Octagon Capital Advisors LP Portfolio Holdings

Octagon Capital Advisors LP

  • $263 Million
  • Q2 2025

Octagon Capital Advisors LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $263 Million distributed in 30 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Verona Pharma PLC with a value of $31.9M, Taysha Gene Therapies, Inc. with a value of $29.1M, Gossamer Bio, Inc. with a value of $22.6M, Ocular Therapeutix, Inc with a value of $22.5M, and Merus N.V. with a value of $20.5M.

Examining the 13F form we can see an decrease of $37.1M in the current position value, from $301M to 263M.

Octagon Capital Advisors LP is based out at New York, NY

Below you can find more details about Octagon Capital Advisors LP portfolio as well as his latest detailed transactions.

Portfolio value $263 Million
Healthcare: $263 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$6.41B
$31.9 Million 12.1% of portfolio
337,000
Q2 2025 Added 55.11%
$141M
$29.1 Million 11.04% of portfolio
12,592,500
Q2 2025 Added 17.69%
$181M
$22.6 Million 8.57% of portfolio
18,350,000
Q1 2025 Added 1,187.72%
$961M
$22.5 Million 8.54% of portfolio
2,425,000
Q1 2025 Added 719.26%
$2.93B
$20.5 Million 7.77% of portfolio
389,000
Q2 2025 Added 26.3%
$428M
$20.1 Million 7.62% of portfolio
3,672,000
Q2 2025 Added 10.54%
$760M
$19.8 Million 7.53% of portfolio
2,763,000
Q1 2025 Added 31.95%
$2.63B
$15.6 Million 5.94% of portfolio
903,500
Q2 2025 Reduced 56.85%
$504M
$15 Million 5.69% of portfolio
7,691,334
Q2 2025 Reduced 2.64%
$301M
$14.4 Million 5.47% of portfolio
1,273,333
Q2 2025 Reduced 7.06%
$1.61B
$13.5 Million 5.14% of portfolio
1,030,000
Q2 2025 Reduced 27.72%
$712M
$11.8 Million 4.49% of portfolio
672,595
Q2 2025 Reduced 12.63%
$2.18B
$11.6 Million 4.41% of portfolio
266,000
Q2 2025 New
$53.2M
$7.11 Million 2.7% of portfolio
3,820,000
Q2 2025 Added 7.55%
$2.04B
$6.99 Million 2.65% of portfolio
148,000
Q2 2025 Reduced 50.0%
$191M
$889,000 0.34% of portfolio
700,000
Q2 2025 Reduced 86.37%
Unicycive Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Arrivent Biopharma Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 5.5%
Tourmaline Bio Inc
-
$0 0.0% of portfolio
-
Q1 2025 Reduced 77.88%
$0
$0 0.0% of portfolio
1,350,000
Q2 2025 Added 116.0%
Corbus Pharmaceuticals Hldgs
-
$0 0.0% of portfolio
-
Q1 2025 Reduced 68.61%
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 99.44%
Dbv Technologies S A
-
$0 0.0% of portfolio
-
Q2 2025 New
Neurogene Inc
-
$0 0.0% of portfolio
-
Q1 2025 Reduced 77.88%
Mind Medicine Mindmed Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 29.42%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2025 Added 13.71%
Maze Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 62.04%
Helix Acquisition Corp Ii
-
$0 0.0% of portfolio
-
Q1 2025 New
Abivax Sa
-
$0 0.0% of portfolio
-
Q2 2025 Added 3.01%

Summary

  • Portfolio
  • No. of Stocks 30
  • Current Value $263 Million
  • Prior Value $301 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 3 stocks
  • Additional Purchases 7 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 12 stocks
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email